AstraZeneca: positive results in two trials

(CercleFinance.com) - The pharmaceutical group has announced that Calquence has shown long-term efficacy and tolerability for patients with chronic lymphocytic leukemia in two trials.


The ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for patients not previously treated, after more than four years.

In the final ASCEND analysis, approximately 82% of patients with relapsed or refractory CLL treated with Calquence remained alive and free of disease progression after 18 months, compared to 48% of patients on rituximab in combination with idelalisib or bendamustine.

Richard R. Furman, Director of the CLL Research Center, Weill Cornell Medicine, said, “The safety profile of acalabrutinib makes treatment to progression an important and plausible option for patients.”
The results will be presented at the virtual edition of the 25th annual congress of the European Haematology Association (EHA) from 11 to 14 June 2020.


Copyright (c) 2020 CercleFinance.com. All rights reserved.